

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 September 2021 (02.09.2021)




(10) International Publication Number
WO 2021/173729 A2

- (51) International Patent Classification:
C12N 15/11 (2006.01)
- (21) International Application Number:
PCT/US2021/019488
- (22) International Filing Date:
24 February 2021 (24.02.2021)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
62/983,568 28 February 2020 (28.02.2020) US
63/010,476 15 April 2020 (15.04.2020) US
- (71) Applicant: GENENTECH, INC. [US/US]; 1 DNA Way, South San Francisco, CA 94080 (US).
- (72) Inventors: MURTHY, Aditya, Krishna; 1 DNA Way, South San Francisco, CA 94080 (US). OH, Jaehak; 1 DNA Way, South San Francisco, CA 94080 (US). BOHLEN, Christopher, John; 1 DNA Way, South San Francisco, CA 94080 (US). FREUND, Emily, Crane; 1 DNA Way, South San Francisco, CA 94080 (US). HALEY, Benjamin, Joseph; 1 DNA Way, South San Francisco, CA 94080 (US). LOCK, Jaclyn; 1 DNA Way, South San Francisco, CA 94080 (US).
- (74) Agent: CHEN, Yuwei et al.; Mintz Levin Cohn Ferris Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: EFFICIENT GENOME EDITING IN PRIMARY MYELOID CELLS

FIG. 2E



(57) Abstract: Provided herein, *inter alia*, are compositions, methods, and systems for efficient genetic manipulation of myeloid cells without the use of viral vectors. Further provided are strategies for gene disruption in primary myeloid cells (*e.g.* of human and murine origin) using electroporation-based delivery of Cas/ribonuclear proteins (RNPs). Methods provided herein including embodiments thereof can provide near population-level genetic knockout of single and multiple targets in a range of cell types without selection or enrichment. Cellular fitness and response to immunological stimuli may be unaffected by the gene editing process.

[Continued on next page]

WO 2021/173729 A2

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*